P0121 Cancer care performance and survival outcomes at a private cancer centre in Malaysia

Background GLOBOCAN12 recently reported high cancer mortality in Malaysia, a developing country, suggesting its cancer care is under-performing. Methods All women with breast cancer treated at a large cancer centre between 2008 and 2012 were enrolled for this observational cohort study. Patients enrolled from 2011 were also prospectively followed up for 12 months after diagnosis to assess their care performance. The performance metrics were from QOPI, ASCO–NCCN, and local guidelines. Mortality outcome was ascertained through record linkage with the national death register and independently verified. Findings One hundred and thirteen patients treated in 2011 were included for care performance analysis. Pathology reports confirmed malignancy in all women. Surgery was done within 2 months of diagnosis for 90 (99%) of 91 women with stage I to III breast cancer. Chemotherapy was given to 21 (88%) of 24 women with stage I to III hormone-receptor negative breast cancer within 4 months. Radiation therapy for stage I to III breast cancer after breast conserving surgery within 1 year was given to 25 (81%) of 31 eligible patients. Radiation therapy for stage I to III breast cancer with node positive after mastectomy within 1 year was given to 15 (83%) of 18 eligible women. Tamoxifen or an aromatase inhibitor was given to women with stage I to III hormone-receptor positive breast cancer within 1 year to 60 (88%) of 68 eligible women. Trastuzumab for stage I to III HER2-positive breast cancer was given within 4 months to 13 (57%) of 23 eligible women. 601 patients treated between 2008 and 2012 were included for survival analysis. The overall relative survival at 5 years was 91% (age standardised 91%); relative survival for stage I, II, III, and IV cancers were 100%, 96%, 78%, and 40%, respectively. Interpretation These results are comparable to any leading centres in developed countries.